When many people read about the possible price point for Scenesse for EPP in the analyst / company reports, there was a collective sticker shock.
I'm not referring to the price of the drug in Italy, but the expected price of the drug if it gets formal FDA or EMA approval.
I had felt that it's one thing to price the drug to ensure a profit, but I wondered if it was really necessary to price the drug as high as some of the price points we've seen.
Now KV Pharmaceuticals, a stock that I got in at around $1.75 earlier this year to witness a 12 bagger (went over $13 a month later), is going to be investigated for price gouging if U.S. Senator Brown has his way.
Biotechs and pharmas cannot just price a drug at whatever price point they choose. It's a different industry than most other free market industries.
We're not sure what price point Clinuvel will select upon approval, but I hope they keep this in mind. In this day and age, it's much easier to mobolize a grassroots effort to get the attention of legislators.
- Forums
- ASX - By Stock
- CUV
- interesting pricing gouging case
interesting pricing gouging case
-
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$14.12 |
Change
0.250(1.80%) |
Mkt cap ! $706.8M |
Open | High | Low | Value | Volume |
$13.90 | $14.17 | $13.90 | $675.2K | 48.01K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 293 | $14.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.12 | 261 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 900 | 14.000 |
1 | 729 | 13.950 |
1 | 2000 | 13.910 |
2 | 539 | 13.860 |
1 | 600 | 13.850 |
Price($) | Vol. | No. |
---|---|---|
14.250 | 500 | 1 |
14.280 | 833 | 1 |
14.430 | 668 | 1 |
14.460 | 709 | 1 |
14.560 | 5000 | 1 |
Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |